AMGEN INC (AMGN) — SEC Financial Statements & Analysis

AMGEN INC (AMGN) is a biological products, (no diagnostic substances) company, incorporated in DE. AMGEN INC trades on Nasdaq as: AMGN. AMGEN INC (AMGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, AMGEN INC carries a market cap of $194.41B, a P/E ratio of 22.24x, a P/B ratio of 16.63x, a P/S ratio of 5.10x, an enterprise value of $237.72B, and an EV/EBITDA multiple of 14.77x. On profitability, it posts a gross margin of 69.52%, an operating margin of 29.99%, a net margin of 22.95%, a Return on Equity (ROE) of 91.47%, a Return on Assets (ROA) of 9.53%, and a Return on Invested Capital (ROIC) of 17.33%. Per share, it reports EPS of $16.19, diluted EPS of $16.07, free cash flow per share of $18.84, and a dividend per share of $9.79. Over the trailing year, it posted revenue growth of 9.10% year-over-year, net income growth of 32.09% year-over-year, and EPS growth of 31.60% year-over-year. On the balance sheet, it maintains a current ratio of 1.37x, a quick ratio of 1.13x, working capital of $9.46B, a debt-to-equity ratio of 2.18x, a debt ratio of 0.27, an interest coverage ratio of 4.28x, free cash flow of $10.18B (TTM), and net debt of $43.31B. Figures sourced from SEC EDGAR.

Market Cap

$194.41B

P/E TTM

22.24x

EPS TTM

$16.19

P/B TTM

16.63x

ROE TTM

91.47%

ROA TTM

9.53%

Debt To Equity

2.18x

Free Cash Flow TTM

$10.18B

Net Revenue TTM Growth 1Y

9.10%

Data as of 2026-06-30 · Source: SEC EDGAR